相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The political economy of austerity and healthcare: Cross-national analysis of expenditure changes in 27 European nations 1995-2011
Aaron Reeves et al.
HEALTH POLICY (2014)
Estimating the budget impact of orphan drugs in Sweden and France 2013-2020
Adam Hutchings et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
Multicriteria Decision Analysis in the Reimbursement of New Medical Technologies: Real-World Experiences from Hungary
Dora Endrei et al.
VALUE IN HEALTH (2014)
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU
Roberta Joppi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE-BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS-SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN
Warren G. Linley et al.
HEALTH ECONOMICS (2013)
A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines
Jon Sussex et al.
VALUE IN HEALTH (2013)
Prioritizing treatment of rare diseases: A survey of preferences of Norwegian doctors
Arna S. Desser
SOCIAL SCIENCE & MEDICINE (2013)
The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries
John T. Matthews et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2013)
Orphan drug development: an economically viable strategy for biopharma R&D
Kiran N. Meekings et al.
DRUG DISCOVERY TODAY (2012)
Personalized medicine: hope or hype?
Keyan Salari et al.
EUROPEAN HEART JOURNAL (2012)
Time to revisit the orphan drug law
Silvio Garattini
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Which ORPHANS Will Find a HOME? The Rule of Rescue in Resource Allocation for Rare Diseases
Emily A. Largent et al.
HASTINGS CENTER REPORT (2012)
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
Eline Picavet et al.
HEALTH POLICY (2012)
Cystic fibrosis in an era of genomically guided therapy
P. M. Barrett et al.
HUMAN MOLECULAR GENETICS (2012)
A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
Wim Pinxten et al.
JOURNAL OF MEDICAL ETHICS (2012)
The High Cost of Cancer Drugs and What We Can Do About It
Mustaqeem Siddiqui et al.
MAYO CLINIC PROCEEDINGS (2012)
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Wills Hughes-Wilson et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe
Maurizio Luisetti et al.
RESPIRATORY MEDICINE (2012)
DEFINING ELEMENTS OF VALUE FOR RARE DISEASE TREATMENTS
A. Hutchings et al.
VALUE IN HEALTH (2012)
An Evaluation Framework for Funding Drugs for Rare Diseases
Eric Winquist et al.
VALUE IN HEALTH (2012)
What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward
Panos Kanavos et al.
VALUE IN HEALTH (2012)
Access to orphan drugs in Europe: current and future issues
Morgane Michel et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2012)
Difficult decisions in times of constraint: Criteria based Resource Allocation in the Vancouver Coastal Health Authority
Craig Mitton et al.
BMC HEALTH SERVICES RESEARCH (2011)
DISCOUNTING AND DECISION MAKING IN THE ECONOMIC EVALUATION OF HEALTH-CARE TECHNOLOGIES
Karl Claxton et al.
HEALTH ECONOMICS (2011)
Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
Aaron S. Kesselheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Research challenges in central nervous system manifestations of inborn errors of metabolism
P. I. Dickson et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Pricing and reimbursement of orphan drugs: the need for more transparency
Steven Simoens
ORPHANET JOURNAL OF RARE DISEASES (2011)
Estimating the budget impact of orphan medicines in Europe: 2010-2020
Carina Schey et al.
ORPHANET JOURNAL OF RARE DISEASES (2011)
To Fund or Not to Fund Development of a Decision-Making Framework for the Coverage of New Health Technologies
Tania Stafinski et al.
PHARMACOECONOMICS (2011)
Health Technology Funding Decision-Making Processes Around the World The Same, Yet Different
Tania Stafinski et al.
PHARMACOECONOMICS (2011)
Drugs for Rare Diseases: Influence of Orphan Designation Status on Price
Eline Picavet et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2011)
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
Tania Stafinski et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2011)
A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study
Emmanouil Mentzakis et al.
HEALTH ECONOMICS POLICY AND LAW (2011)
Reforming Off-Label Promotion to Enhance Orphan Disease Treatment
Bryan A. Liang et al.
SCIENCE (2010)
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013
Alain Denis et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES
J. Clarke et al.
VALUE IN HEALTH (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
Assessing the economic challenges posed by orphan drugs
Michael F. Drummond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2007)
Rare essentials: drugs for rare diseases as essential medicines
Pieter Stolk et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2006)
Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy
JTR Clarke
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
分享论文
